PTGX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PTGX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Protagonist Therapeutics's quarterly net PPE declined from Jun. 2023 ($3.30 Mil) to Sep. 2023 ($2.93 Mil) and declined from Sep. 2023 ($2.93 Mil) to Dec. 2023 ($2.15 Mil).
Protagonist Therapeutics's annual net PPE declined from Dec. 2021 ($6.73 Mil) to Dec. 2022 ($4.63 Mil) and declined from Dec. 2022 ($4.63 Mil) to Dec. 2023 ($2.15 Mil).
The historical data trend for Protagonist Therapeutics's Property, Plant and Equipment can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protagonist Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Property, Plant and Equipment | Get a 7-Day Free Trial | 7.72 | 6.41 | 6.73 | 4.63 | 2.15 |
Protagonist Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Property, Plant and Equipment | Get a 7-Day Free Trial | 4.63 | 3.90 | 3.30 | 2.93 | 2.15 |
Property, Plant and Equipment (PPE) are the fixed assets of the companyFixed assets are also known as non-current assets.
Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.
Some of the most common parts of property, plant, and equipment are:
Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:
There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.
The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.
For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.
All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.
The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.
Protagonist Therapeutics (NAS:PTGX) Property, Plant and Equipment Explanation
A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.
Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.
Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.
Thank you for viewing the detailed overview of Protagonist Therapeutics's Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.
Suneel Gupta | officer: Chief Development Officer | 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560 |
Patel Dinesh V Ph D | director, officer: President and CEO | C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035 |
Arturo Md Molina | officer: Chief Medical Officer | 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024 |
Swisher Daniel N Jr | director | C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080 |
Lewis T Williams | director | C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Bryan Giraudo | director | 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560 |
Harold E Selick | director | |
Sarah B. Noonberg | director | 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Sarah A O'dowd | director | 3185 LAURELVIEW COURT, FREMONT CA 94538 |
William D. Waddill | director | C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080 |
Asif Ali | officer: Chief Financial Officer | 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560 |
Donald A. Kalkofen | officer: Chief Financial Officer | 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560 |
David Y Liu | officer: Chief Scientific Officer | C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035 |
Chaitan Phd Khosla | director | 3832 BAY CENTER PLACE, HAYWARD CA 94545 |
Richard S Shame | officer: Chief Medical Officer | C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 06-06-2023
By PRNewswire PRNewswire • 05-11-2023
By ACCESSWIRE ACCESSWIRE • 06-02-2023
By PRNewswire PRNewswire • 05-11-2023
By ACCESSWIRE • 11-02-2023
By PRNewswire PRNewswire • 12-21-2022
By ACCESSWIRE • 10-04-2023
By PRNewswire PRNewswire • 12-01-2022
By ACCESSWIRE • 11-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.